



Illuminating The Undiscovered Structural Surfaceome For Targeted Therapeutics




Investor Presentation
December 2024



Cancer is Inherently Non-Native





Normal Tissue



Tumor Tissue

The structural surfaceome can be exploited as drug targets






→ Illuminating the Unknown

Uncovering A Universe of New Targets


Tumor-specific Surface Protein Conformations (SPC Targets)



We Are Pioneering A New Class Of Targets



Healthy cells



Tumor cells

Cancer-specific Surface Protein Conformations (SPC)
as novel targets


- **Exceptional Specificity**
 - Eliminate 'on target, off tumor' toxicity
 - Allow higher dosing to maximize efficacy
- **Invisible to standard target discovery approaches**





The Only Platform Capable of Identifying SPC Targets

PROPRIETARY TARGET ID PLATFORM






Cutting Edge Proprietary Platform



Powered by High Throughput Structural Proteomics and AI-enabled Computation

Patient-derived samples

Partnerships with NCI-designated cancer centers



SPC Target ID Platform




Drugging SPC Targets Requires a Novel Approach

Challenge: Conformation-Specific Binding

- Traditional platforms screen for affinity but fail to address specificity against SPC targets

Our Solution: Structure-Based Discovery

- EPIC: Epitope-targeted In Cell Antibody Discovery
- Structure-Based Antigen Design for screen and counter-screening for maximizing precision and minimizing on-target, off-tissue toxicity
- AI-enabled modeling, constrained with structural data, for rapid and effective engineering: affinity, specificity, cross-reactivity



EPIC Ab Discovery Platform Extensively Validated By Partners



30+ paid collaborators
including 8 of the top
pharmaceutical companies
Positive cash flow



4 Patents
IP protection for industry
leading technologies





Preclinical Pipeline
First-in-class programs
against novel targets
Initial focus: **Oncology**





Internal Pipeline

Initial Focus: Oncology



We are Biologists + Engineers + Explorers



Faraz Choudhury, PhD
Founder and CEO

Technology Co-inventor
 PhD in Engineering, Graduate of Entrepreneurship (UW Business)



Michael Sussman, PhD
Co-Founder

KOL and leading expert in protein biochemistry
 Founder of NimbleGen (acquired by Roche for \$273MM)



Neal Goodwin, PhD
CSO

Co-founder and former CSO of ProNAi Therapeutics (Sierra Oncology; NASDAQ: SRRR; acquired by GSK)



CMO

To be hired in 2026

ADVISORS

Discovery



Gavin Thurston, PhD
 Former SVP of Oncology Regeneron

Data Science



Ian McFadyen, PhD
 Former VP of Data Science at Moderna

IND/Regulatory



Ron Christopher, PhD, DABT, FCP
 30+ years of experience. >25 INDs, 4 NDAs, 3 MAAs
 Ex-Takeda and Ambit

Clinical



Martin Carroll, MD
 Professor of Medicine (Hematology-Oncology), UPenn
 Leading Expert and KOL in AML

50+ YEARS INDUSTRY EXPERIENCE



Inventors of the core technology and leading experts in oncology and antibody discovery



Previous experience in technology commercialization with successful exits





Faraz A Choudhury, Ph.D.
Co-founder and CEO

faraz@immutoscientific.com

608.733.2069

www.immutotherapeutics.com